GeneRulor deeply cultivates the field of protein expression and purification, offering a comprehensive, multi-species platform tailored to diverse research and industrial scenarios. Our versatile infrastructure seamlessly integrates a highly efficient E. coli prokaryotic system for rapid, expedited turnarounds; a robust mammalian cell system—encompassing both transient transfection and stable cell line generation—to ensure precise folding and complex post-translational modifications (PTMs) for critical antibodies; and a scalable yeast system that flawlessly balances eukaryotic expression fidelity with operational simplicity. Leveraging mature technical expertise, our end-to-end services support the entire development lifecycle—from early-stage structural analysis and pilot studies to large-scale biomanufacturing—seamlessly accelerating your functional discoveries and therapeutic innovations.
Viral vectors are indispensable core tools driving advancements in gene therapy, cell therapy, and vaccine development. To address the industry's complex demands for vector engineering, scalable biomanufacturing, and rigorous quality control, GeneRulor provides an end-to-end CRO/CDMO platform. Specializing in lentiviral, adeno-associated virus (AAV), adenoviral, and novel virus-like particle (VLP) technologies, our comprehensive infrastructure encompasses seven major vector systems. From initial plasmid construction through to final GMP release, we deliver highly integrated, regulatory-compliant solutions to seamlessly accelerate your therapeutic pipeline from bench to clinic.
